TITLE

Retina Specialists: A Grim View of AMD

PUB. DATE
August 2004
SOURCE
Review of Ophthalmology;Aug2004, Vol. 11 Issue 8, p12
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Presents results from the online survey regarding wet age-related macular degeneration (AMD), commissioned by the Eyetech Pharmaceuticals and Pfizer, in consultation with the Lighthouse International. Percentage of specialists who were alarmed by the increasing number of cases of wet AMD; Effect of the rising incidence of wet AMD on direct cost to the health-care system; Impact of the rising incidence of wet AMD on the finances of patients and families.
ACCESSION #
14146675

 

Related Articles

  • Changes in pegaptanib labeling prompted by adverse reactions. Charters, Lynda // Ophthalmology Times;5/15/2006, Vol. 31 Issue 10, p8 

    The article focuses on the changes in the product labeling for pegaptanib sodium injection made by OSI Pharmaceuticals Inc., Eyetech Pharmaceuticals Inc. and Pfizer Inc. The injection was approved by the United States Food and Drug Administration for the treatment of neovascular age-related...

  • FDA Approves Eyetech/Pfizers Macugen.  // Review of Ophthalmology;Jan2005, Vol. 12 Issue 1, p4 

    The article reports that the U.S. food and Drug Administration has approved Macugen injection for the treatment of neovascular age-related macular degeneration. The injection has been developed by Eyetech Pharmaceuticals Inc. and Pfizer Inc. Macugen is the first in a new class of ophthalmic...

  • Macugen account goes to Medicus. Arnold, Matthew // Medical Marketing & Media;May2004, Vol. 39 Issue 5, p10 

    Reports that Pfizer and Eyetech Pharmaceuticals have appointed Medicus New York to handle professional advertising for their co-marketed Macugen drug for macular degeneration. Account is Medicus Group's first formal assignment from Pfizer; Parent firm Publicis Groupe's work with Pfizer in the...

  • AMD: A Revolution In Therapy Begins. Rosenfeld, Philip // Review of Ophthalmology;Mar2005, Vol. 12 Issue 3, p96 

    Assesses the effectiveness of Macugen, an ophthalmic drug from Eyetech Pharmaceuticals Inc. and Pfizer Inc., that specifically targets the vascular endothelial growth factor (VEGF) to treat age-related macular degeneration. Correlation between elevated levels of VEGF and various diseases that...

  • Priority review for Pfizer, Eyetech AMD drug.  // PharmaWatch: Biotechnology;October 2004, Vol. 3 Issue 10, p11 

    The article reports that Macugen, a treatment for age-related macular degeneration jointly developed by Pfizer Corp. and Eyetech Pharmaceuticals Inc. has been granted a priority review designation by the U.S.Food and Drug Administration (FDA). The companies submitted the final portion of the new...

  • New Eye Drug Approved. Mirasol, Feliza // Chemical Market Reporter;1/10/2005, Vol. 267 Issue 2, p10 

    Reports on the approval of the U.S. Food and Drug Administration to new eye drug Macugen of Eyetech Pharmaceuticals Inc. and co-developer Pfizer Inc. Use of Macugen in the treatment of neovascular age-related macular degeneration; Price of the drug; Development of Macugen.

  • Pegaptanib sodium injection available for treatment of AMD-related CNV. Guttman, Cheryl // Ophthalmology Times;1/15/2005, Vol. 30 Issue 2, p1 

    This article reports that the FDA approved pegaptanib sodium injection by Macugen, Eyetech Pharmaceuticals and Pfizer Ophthalmics for the treatment of neovascular age-related macular degeneration (AMD) on December 17. With the regulatory agency's decision, pegaptanib sodium became the first...

  • Pipeline.  // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p12 

    The article presents news from the pharmaceutical industry. Pfizer Inc. received a setback when the FDA classified its newly approved nerve pain drug Lyrica as a controlled substance, resulting in additional requirements for doctors and pharmacists. Pfizer had been counting on Lyrica to offset...

  • Pfizer, Eyetech in deal for AMD, DME therapy.  // Ophthalmology Times;2/1/2003, Vol. 28 Issue 3, p6 

    Reports on the deal between Pfizer Inc. and Eyetech Pharmaceuticals Inc. to develop and commercialize pegaptanib sodium Macugen in the U.S. Terms of the deal; Sales projected by Eyetech upon approval of the drug; Responsibility to Pfizer to finance the manufacturing cost of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics